NASDAQ:RNXT

RenovoRx Q4 2024 Earnings Results & Report

RenovoRx logo
$1.04 -0.08 (-7.14%)
As of 02:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

RenovoRx missed analyst expectations on both earnings and revenue in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$0.13 versus the -$0.12 consensus estimate, while revenue of $40 thousand fell short of the $168 thousand estimate by $128 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
8:30 AM ET

RenovoRx EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

RenovoRx Revenue Results

Actual Revenue
$40 thousand
Expected Revenue
$168 thousand
Beat/Miss
Missed by -$128.00 thousand
YoY Revenue Growth
N/A

RenovoRx Q4 2024 Earnings FAQ

RenovoRx (NASDAQ:RNXT) reported earnings of -$0.13 per share for Q4 2024, missing the consensus estimate of -$0.12. The report was announced on Monday, March 31, 2025.

RenovoRx reported revenue of $40 thousand for Q4 2024, against a consensus estimate of $168 thousand.

RenovoRx Earnings Headlines

Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Brokers Issue Forecasts for RenovoRx Q1 Earnings
HC Wainwright Issues Negative Outlook for RenovoRx Earnings
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body.

The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.

RenovoRx is based in Mountain View, California. Its clinical development program includes the TIGeR-PaC study, which is evaluating its treatment approach in pancreatic cancer.

View RenovoRx Profile